{"entity":{"id":"nct07461454","kind":"trial","name":"YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer","aka":[],"tldr":"A phase 3 trial testing YL202 in HR-positive / HER2-negative breast cancer, now recruiting.","summary":"YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer is a phase 3 interventional study registered as NCT07461454, led by MediLink Therapeutics (Suzhou), and recruiting on the registry. Official title: A Randomised, Open-label, Multicenter, Phase 3 Study of YL202 Versus Treatment of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer Who Had Failed at Least One Line of Chemotherapy. Planned enrolment is 376 participants (estimated). The study started in 2026-03-17 and primary completion is expected in 2027-12-31. No results have been posted on ClinicalTrials.gov.","status":"recruiting","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov NCT07461454","url":"https://clinicaltrials.gov/study/NCT07461454"}],"tags":["ctgov-ingest"],"related":[],"cancers":["breast-hr-positive"],"sections":[],"technologies":[],"targets":[],"drugs":["yl202"],"companies":["medilink"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07461454","phase":"3","setting":"A Randomized, Open-label, Multicenter, Phase 3 Study of YL202 Versus Treatment of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer Who Had Failed at Least One Line of Chemotherapy","sponsor":"MediLink Therapeutics (Suzhou)","participation":[{"nct":"NCT07461454","source":"https://clinicaltrials.gov/study/NCT07461454","fetchedAt":"2026-10-07T16:55:45.930Z","studySha256":"441b686c483892e144880b35ec08312dc4fe7d4ca623481a13d4f5e0182f2730","overallStatus":"RECRUITING","lastUpdatePosted":"2026-05-26","leadSponsor":"MediLink Therapeutics (Suzhou) Co., Ltd.","collaboratorCount":0,"minimumAge":"18 Years","maximumAge":"75 Years","sex":"FEMALE","healthyVolunteers":false,"hasEligibility":true,"enrolment":376,"enrolmentType":"ESTIMATED","siteCount":1,"recruitingSiteCount":1,"countries":["China"]}],"started":"2026-03-17","startedType":"actual","enrolled":376,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07461454/","neighbours":{"cancer":[{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"}],"drug":[{"id":"yl202","kind":"drug","name":"YL202","route":"/drugs/yl202/"}],"company":[{"id":"medilink","kind":"company","name":"MediLink Therapeutics","route":"/companies/medilink/"}]}}